Palisade Bio Inc. is a late-stage biopharma company advancing therapies which help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio Inc., formerly known as Seneca Biopharma Inc., is based in CARLSBAD, Calif.
| Revenue (Most Recent Fiscal Year) | $0.25M |
| Net Income (Most Recent Fiscal Year) | $-14.44M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.60 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -178.96% |
| Return on Assets (Trailing 12 Months) | -127.35% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.84 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.84 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.71 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.47 |
| Earnings per Share (Most Recent Fiscal Year) | $-10.19 |
| Diluted Earnings per Share (Trailing 12 Months) | $-6.80 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 4.80M |
| Free Float | 4.64M |
| Market Capitalization | $3.48M |
| Average Volume (Last 20 Days) | 0.41M |
| Beta (Past 60 Months) | 1.36 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.28% |
| Percentage Held By Institutions (Latest 13F Reports) | 11.79% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |